Azacitidine Treatment in Patients with Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia Type 2 and Acute Myeloid Leukemia According to their Cytogenetic Findings

Introduction: Azacitidine is one of the hypomethylating agents available for the treatment of elderly patients with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). It is also used as an appropriate treatment of chronic myelomonocytic leukemia (CMML) in the real life setting. As treat...

Full description

Bibliographic Details

Published in:	Acta Medica Bulgarica
Main Authors:	Nikolova D., Yordanov A., Radinov A.
Format:	Article
Language:	English
Published:	Sciendo 2021-10-01
Subjects:	azacitidine (aza, vidaza®) monitoring blood count parameters toxicity cytogenetic findings
Online Access:	https://doi.org/10.2478/amb-2021-0030